Showing results (301-310 of 351) with videos related to
Sort By:
Pageof 36
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 22, 2018
Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitusNorio Akuta, Yusuke Kawamura, Chizuru Watanabe, et al.Oncology|September 14, 2022
The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based AnalysisNozomu Muraishi, Yusuke Kawamura, Norio Akuta, et al.Cancers|August 12, 2023
Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular CarcinomaYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|October 28, 2009
Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevirFumitaka Suzuki, Yoshiyuki Suzuki, Norio Akuta, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 12, 2018
Primary liver carcinoma with sarcomatous changes: Analysis of 10 casesKazuki Ohya, Satoshi Saitoh, Shunichiro Fujiyama, et al.Clinical Journal of Gastroenterology|January 11, 2021
An encapsulated bulky abdominal abscess due to amoebaSoichi Iritani, Yusuke Kawamura, Daiki Yamashige, et al.Liver Cancer|February 20, 2020
18F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to LenvatinibYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.Clinical Journal of Gastroenterology|November 7, 2022
Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinomaYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.Oncology|March 1, 2022
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular CarcinomaYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 3, 2023
Impact of fibrosis on liver-related event incidence in nonalcoholic fatty liver disease: A multicenter observational studyKazuaki Chayama, Akira Hiramatsu, Toshihide Shima, et al.Pageof 36